QV Bioelectronics USA cooperation feasibility study

美国QV生物电子合作可行性研究

• 批准号: 10020166
• 金额: $ 2.3万
• 依托单位: QV BIOELECTRONICS LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10020166
• 关键词: QV; Bioelectronics; USA; cooperation; feasibility

Glioblastoma is the most common and aggressive primary adult brain cancer. Global incidence is 3-5/100,000 persons and rising, with c.3000 UK diagnoses/year. There is no cure and patient life expectancy is just 14-months post-diagnosis on average.Electric field therapy is a new form of cancer treatment applied after tumour resection that directly interferes with cell division, slowing tumour recurrence and prolonging life. However, the single marketed device for glioblastoma is not recommended for use on the NHS by NICE due to poor patient quality-of-life and low cost-effectiveness.QV Bioelectronics (QVB) are developing GRACE, a novel implant that delivers electric field therapy in a focal and continuous manner, potentially doubling glioblastoma patient life expectancy, leading to potential improved patient outcomes whilst overcoming quality-of-life issues associated with existing solutions. QVB is seeking to access partners in the US who have specialist knowledge, technologies and capital available to bring the GRACE device to market. QVB's device is still undergoing pre-clinical development and will not be ready to be prescribed to patients for several years. QVB's technology will be expanded to other types of brain tumours in future, creating a combined global market opportunity worth over £5Bn/year, whilst providing a new treatment for NHS patients. This will generate UK jobs and help to cement the UK's position as global leaders in the growing field of bioelectronics.

胶质母细胞瘤是最常见和侵略性的原发性成人脑癌。全球事件是3-5/100,000人，并且有上升，英国诊断/年为C.3000。平均而言，无法治愈，预期寿命仅在诊断后14个月。电场治疗是肿瘤切除后采用癌症治疗的一种新形式，直接干扰细胞分裂，减慢肿瘤复发并延长寿命。然而，由于患者寿命差和成本效益低，不建议在NHS上使用单一的用于胶质母细胞瘤的单一销售设备。QV生物电位分析（QVB）正在开发Grace（QVB）正在开发Grace，这是一种新颖的植入物，该植入物可在焦点和连续的方式中提供电力现场疗法，潜在地与现有的患者相关的质量相关的质量，以促进胶粘剂的生活，以至于越来越多地与胶状瘤相关的质量相关，以至于越来越多地融合了葡萄糖的生活。解决方案。 QVB正在寻求访问美国具有专业知识，技术和资本的合作伙伴，以将宽限期设备推向市场。 QVB的设备仍在进行临床前开发，并且几年内都不会为患者开处方。 QVB的技术将来将扩展到其他类型的脑肿瘤，从而创造出每年价值超过50亿英镑的全球市场机会，同时为NHS患者提供新的治疗方法。这将产生英国就业机会，并有助于巩固英国在不断增长的生物电子领域的全球领导者的地位。